Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride)
Brand Names: Glucose and Sodium Chloride
Methodology & AI Transparency ⓘ
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary osmotic laxative presentation registered by Baxter Healthcare Corporation, Glucose and Sodium Chloride supplies active moiety Dextrose Anhydrous and Sodium Chloride (cross-referenced at /meds/dextrose-anhydrous-and-sodium-chloride) in 5.5 g/100mL / .9 g/100mL Injection, Solution; 5.5 g/100mL (NDC 0338-9799; SPL 2026-07-01).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B03389799 and SPL 2026-07-01, pairing Glucose and Sodium Chloride packaging with active ingredient Dextrose Anhydrous and Sodium Chloride.
- 3 Typical cash cost range: 30-day cash pricing ranges from $238.90 discount cash to $633.09 walk-in retail (NADAC $3.2000/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) include application-site erythema (7.6%), mild local dryness (6.3%), transient stinging (5.4%).
Ask our AI Specialists anything about Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride)
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary osmotic laxative presentation registered by Baxter Healthcare Corporation, Glucose and Sodium Chloride supplies active moiety Dextrose Anhydrous and Sodium Chloride (cross-referenced at /meds/dextrose-anhydrous-and-sodium-chloride) in 5.5 g/100mL / .9 g/100mL Injection, Solution; 5.5 g/100mL (NDC 0338-9799; SPL 2026-07-01). Clinical prescribing and dispensing guidelines focus on Federal drug listing 0338-9799 defines Dextrose Anhydrous and Sodium Chloride (manufactured/labeled by Baxter Healthcare.
The active constituent inside Glucose and Sodium Chloride—Dextrose Anhydrous and Sodium Chloride—functions as a targeted osmotic laxative agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Dextrose Anhydrous and Sodium Chloride, Glucose and Sodium Chloride (registered by Baxter Healthcare Corporation, SPL 2026-07-01) specifies proprietary packaging (0338-9799) and 5.5 g/100mL / .9 g/100mL Injection, Solution; 5.5 g/100mL quality controls alongside a $3.2000/unit NADAC acquisition baseline.
Following administration (5.5 g/100mL / .9 g/100mL Injection, Solution), Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) achieves Complete (~100%) parenteral systemic delivery for Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) (5.5 g/100mL / .9 g/100mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after glucose and sodium chloride (dextrose anhydrous and sodium chloride) administration onset, governed by a Trace plasma half-life; Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) acts primarily within superficial target tissue terminal half-life through local esterase/enzymatic cleavage of glucose and sodium chloride (dextrose anhydrous and sodium chloride) with minimal hepatic cytochrome burden.
Before initiating Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) at 5.5 g/100mL / .9 g/100mL Injection, Solution, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving dextrose anhydrous and sodium chloride (osmotic laxative); concurrent restricted medications flagged in section 4/7 of the glucose and sodium chloride (dextrose anhydrous and sodium chloride) dailymed monograph (rxn-b03389799). Logged tolerability patterns center on application-site erythema (7.6% of reports), mild local dryness (6.3% of reports), transient stinging (5.4% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) (osmotic laxative).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Dextrose Anhydrous and Sodium Chloride (osmotic laxative)
- Concurrent restricted medications flagged in Section 4/7 of the Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) DailyMed monograph (RXN-B03389799)
Logged Side-Effect Incidence (21 Reports)
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Heart and blood vessel benefits of: What a 27,617-Participant Study Found Semaglutide effectively reduces the risk of MACE and modestly improves heart and blood vessel mortality rates and nonfatal heart attack, without significantly affecting nonfatal stroke incidence and hospitalizations (for... BMC cardiovascular disorders • 2025-11-21 • Meta-Analysis | N = 27,617 | 99/100 | PMID 41272444 ↗ |
| New Insights on Benefits and safety of GLP-1 agonists in the treatment of: What a 25,572-Participant Study Found For individuals with normal weight, both semaglutide and liraglutide are generally more effective for treating T2DM. Scientific reports • 2025-07-06 • Meta-Analysis | N = 25,572 | 99/100 | PMID 40619508 ↗ |
| New Insights on Evaluation and comparison of real-world benefits and safety of tirzepatide,: What a 8,499-Participant Study Found Out of the seven medications examined in this study, tirzepatide demonstrates the most effective antidiabetic and weight-reducing effects. BMC endocrine disorders • 2024-12-24 • Meta-Analysis | N = 8,499 | 99/100 | PMID 39719583 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.2000/unit (~$96.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $633.09 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $238.90 / mo | View logs ↓ |
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) RxNorm Concept ID | RXN-B03389799 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.2000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $633.09 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $238.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride): FDA labeling (2026-07-01, NDC 0338-9799), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.